Citrulline in Severe Sepsis
Completed · Phase 2 · Has a placebo group
Conditions studied: Severe Sepsis, Acute Lung Injury
In brief
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis is that intravenous L-citrulline will decreased the development or progression of acute lung injury in patients with severe sepsis compared to placebo.
Key facts
- Study ID
- NCT01474863
- Run by
- Vanderbilt University
- People needed
- 72
- Starts
- 2012-08-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2017-06-05
Who can join
Age: 13 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Severe Sepsis
You may not qualify if…
- No Consent
- Malignant or other irreversible condition
- Moribund and not expected to survive 48 hours
- End Stage Liver Disease
- Enrolled in another IND study
- Pregnant or breast feeding female
- Age<13 years old
- Allergy to citrulline or arginine
Where it is running
- Vanderbilt University — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.